CN102459174A - 4-(3-氯-2-氟苯胺基)-7-甲氧基-6-[1-(n-甲基氨基甲酰基甲基)哌啶-4-基]喹唑啉的制备方法 - Google Patents

4-(3-氯-2-氟苯胺基)-7-甲氧基-6-[1-(n-甲基氨基甲酰基甲基)哌啶-4-基]喹唑啉的制备方法 Download PDF

Info

Publication number
CN102459174A
CN102459174A CN2010800288080A CN201080028808A CN102459174A CN 102459174 A CN102459174 A CN 102459174A CN 2010800288080 A CN2010800288080 A CN 2010800288080A CN 201080028808 A CN201080028808 A CN 201080028808A CN 102459174 A CN102459174 A CN 102459174A
Authority
CN
China
Prior art keywords
compound
formula
acid
reaction
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800288080A
Other languages
English (en)
Chinese (zh)
Inventor
K·A·博亚德曼
O·R·坎宁厄姆
W·冈德里
D·D·P·拉芬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN102459174A publication Critical patent/CN102459174A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/12—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CN2010800288080A 2009-04-23 2010-04-22 4-(3-氯-2-氟苯胺基)-7-甲氧基-6-[1-(n-甲基氨基甲酰基甲基)哌啶-4-基]喹唑啉的制备方法 Pending CN102459174A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17199409P 2009-04-23 2009-04-23
US61/171994 2009-04-23
PCT/GB2010/050653 WO2010122340A2 (en) 2009-04-23 2010-04-22 Process 738

Publications (1)

Publication Number Publication Date
CN102459174A true CN102459174A (zh) 2012-05-16

Family

ID=42224659

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800288080A Pending CN102459174A (zh) 2009-04-23 2010-04-22 4-(3-氯-2-氟苯胺基)-7-甲氧基-6-[1-(n-甲基氨基甲酰基甲基)哌啶-4-基]喹唑啉的制备方法

Country Status (14)

Country Link
US (1) US8450482B2 (enExample)
EP (1) EP2421827A2 (enExample)
JP (1) JP2012524769A (enExample)
KR (1) KR20120007059A (enExample)
CN (1) CN102459174A (enExample)
AR (1) AR076407A1 (enExample)
AU (1) AU2010240717A1 (enExample)
BR (1) BRPI1013854A2 (enExample)
CA (1) CA2758610A1 (enExample)
IL (1) IL215388A0 (enExample)
MX (1) MX2011011177A (enExample)
SG (1) SG174893A1 (enExample)
TW (1) TW201041871A (enExample)
WO (1) WO2010122340A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108440420A (zh) * 2018-03-22 2018-08-24 盐城师范学院 酪氨酸激酶抑制剂拉帕替尼及其关键中间体的制备方法
CN108503596A (zh) * 2018-03-14 2018-09-07 盐城师范学院 一种新的厄洛替尼及其中间体的制备方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101272613B1 (ko) 2011-10-05 2013-06-10 한미사이언스 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온 염산염의 제조 방법 및 이에 사용되는 중간체

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023783A1 (en) * 2003-09-05 2005-03-17 Astrazeneca Ab Process for the manufacture of gefitinib
WO2005115145A2 (en) * 2004-05-20 2005-12-08 Wyeth Quinone substituted quinazoline and quinoline kinase inhibitors
CN1882569A (zh) * 2003-09-19 2006-12-20 阿斯利康(瑞典)有限公司 喹唑啉衍生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324597B (en) 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
WO2009138779A1 (en) * 2008-05-13 2009-11-19 Astrazeneca Ab Combination comprising 4- (3-chloro-2-fluoroanilino) -7-meth0xy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxyjquinazoline
BRPI0912170A2 (pt) * 2008-05-13 2015-10-13 Astrazeneca Ab composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023783A1 (en) * 2003-09-05 2005-03-17 Astrazeneca Ab Process for the manufacture of gefitinib
CN1882569A (zh) * 2003-09-19 2006-12-20 阿斯利康(瑞典)有限公司 喹唑啉衍生物
WO2005115145A2 (en) * 2004-05-20 2005-12-08 Wyeth Quinone substituted quinazoline and quinoline kinase inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108503596A (zh) * 2018-03-14 2018-09-07 盐城师范学院 一种新的厄洛替尼及其中间体的制备方法
CN108440420A (zh) * 2018-03-22 2018-08-24 盐城师范学院 酪氨酸激酶抑制剂拉帕替尼及其关键中间体的制备方法

Also Published As

Publication number Publication date
WO2010122340A8 (en) 2011-12-15
SG174893A1 (en) 2011-11-28
EP2421827A2 (en) 2012-02-29
AU2010240717A1 (en) 2011-10-27
JP2012524769A (ja) 2012-10-18
AR076407A1 (es) 2011-06-08
MX2011011177A (es) 2011-11-18
TW201041871A (en) 2010-12-01
IL215388A0 (en) 2011-12-29
WO2010122340A3 (en) 2011-09-09
KR20120007059A (ko) 2012-01-19
US20120108814A1 (en) 2012-05-03
US8450482B2 (en) 2013-05-28
BRPI1013854A2 (pt) 2017-05-16
CA2758610A1 (en) 2010-10-28
WO2010122340A2 (en) 2010-10-28

Similar Documents

Publication Publication Date Title
TWI307339B (en) Quinazoline ditosylate salt comprounds
CN101139345B (zh) 1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨甲酰-苯并呋喃-5-基)-哌嗪盐酸盐的多晶型物
CN103626742B (zh) 激酶的联-芳基间-嘧啶抑制剂
JP2000506151A (ja) ピリミド［５，４―ｄ］ピリミジン、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法
CN1066149C (zh) 用作磷酸二酯酶iv抑制剂的二氮杂䓬并吲哚
JP2000506847A (ja) ４―アミノ―ピリミジン誘導体、これらの化合物を含む医薬品、それらの使用及び製造法
HU227543B1 (en) N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
IL95568A (en) N-substituted-4-pyrimidinamines, a process for their preparation and pharmaceutical compositions containing them
TW200804342A (en) Trisubstituted amine compound
TW201215605A (en) Manufacturing process for pyrimidine derivatives
US20030083336A1 (en) Phenylpiperazinyl derivatives
CZ281698A3 (cs) Pyrimido /5,4-d/pyrimidinové deriváty, způsob jejich výroby a farmaceutický prostředek
IE67288B1 (en) 1-indolyalkyl-4-(alkoxypyrimidinyl) piperazines
TW200840581A (en) Novel pyrimidine derivatives
KR102142797B1 (ko) 피리디닐아미노피리미딘 유도체의 메실레이트 염의 결정질 형태, 그의 제조 방법, 및 그의 용도
SK83697A3 (en) Piperazine-2,5-dione derivatives as modulators of multi-drug resistance
TWI443095B (zh) 新穎鹽
CN101959846B (zh) O-去甲基-文拉法辛盐
JP2025131810A (ja) タンパク質キナーゼ阻害剤としてのヘテロ環化合物の結晶形
WO2005100314A1 (en) Crystalline polymorph of bazedoxifene acetate
TW200846330A (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof
CN102459174A (zh) 4-(3-氯-2-氟苯胺基)-7-甲氧基-6-[1-(n-甲基氨基甲酰基甲基)哌啶-4-基]喹唑啉的制备方法
TW201718516A (zh) 組蛋白去乙醯酶抑制劑之晶形
CN111683934B (zh) (r)-3-(1-(2,3-二氯-4-(吡嗪-2-基)苯基)-2,2,2-三氟乙基)-1-甲基-1-(1-甲基哌啶-4-基)脲的延胡索酸盐、制备方法及其用途
JP2921760B2 (ja) フタルイミド誘導体及びそれら誘導体を含んでなる医薬

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120516